ALS2CL

Across TCGA pan-cancer cohorts, ALS2CL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALS2CL data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ALS2CL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALS2CL expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where ALS2CL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.363	0.834	.024	13	view →
HNSC	DFS	Median	IV	0.915	0.688	.010	13	view →
CCRCC	DFS	Tertile	All	0.950	0.643	.024	6	view →
LUAD	OS	Quartile	II,III,IV	0.337	1.000	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALS2CL–PDAC (DFS)

Open the PDAC breakdown →